Warning: The NCBI web site requires JavaScript to function. more...
Drugs in development: bisphosphonates and metalloproteinase inhibitors.
Catterall JB, Cawston TE.
Arthritis Res Ther. 2003;5(1):12-24. Epub 2002 Nov 8. Review.
Related citations
Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis.
Shaw T, Nixon JS, Bottomley KM.
Expert Opin Investig Drugs. 2000 Jul;9(7):1469-78. Review.
[Bisphosphonates and combined treatments osteoporosis].
Rizzoli R, Ferrari S.
Rev Med Suisse. 2005 Oct 5;1(35):2266, 2269-71. French.
Bisphosphonates in osteoporosis: recent clinical experience.
McClung MR.
Expert Opin Pharmacother. 2000 Jan;1(2):225-38. Review.
Effects of tetracyclines on bone metabolism.
Vernillo AT, Rifkin BR.
Adv Dent Res. 1998 Nov;12(2):56-62. Review.
The role of bisphosphonates in the prevention and treatment of osteoporosis.
Papapoulos SE.
Am J Med. 1993 Nov 30;95(5A):48S-52S. Review.
MMP inhibition and downregulation by bisphosphonates.
Teronen O, Heikkilä P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T.
Ann N Y Acad Sci. 1999 Jun 30;878:453-65.
Bisphosphonates: mechanisms of action and clinical use in osteoporosis--an update.
Fleisch H.
Horm Metab Res. 1997 Mar;29(3):145-50. Review.
Matrix metalloproteinase inhibitors: applications in oncology.
Yip D, Ahmad A, Karapetis CS, Hawkins CA, Harper PG.
Invest New Drugs. 1999;17(4):387-99. Review.
[Diphosphonates--pharmacology and clinical use].
Aaseth J, Syversen U, Førre O.
Tidsskr Nor Laegeforen. 1998 Mar 10;118(7):1064-6. Norwegian.
The potential role of bisphosphonates in prostate cancer.
Oades GM, Coxon J, Colston KW.
Prostate Cancer Prostatic Dis. 2002;5(4):264-72. Review.
New bisphosphonates in osteoporosis.
Osteoporos Int. 1993;3 Suppl 2:S15-22. Review.
Bisphosphonates: preclinical aspects and use in osteoporosis.
Fleisch HA.
Ann Med. 1997 Feb;29(1):55-62. Review.
Clinical trials with bisphosphonates.
Lombardi A, Santora AC.
Ann Ital Med Int. 1992 Jul-Sep;7(3 Suppl):158S-165S. Review.
Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG, Rogers MJ.
Bone. 1999 Jul;25(1):97-106. Review.
The role of bisphosphonates in diseases of childhood.
Srivastava T, Alon US.
Eur J Pediatr. 2003 Nov;162(11):735-51. Epub 2003 Sep 11. Review.
Long-term use of bisphosphonates in osteoporosis.
Watts NB, Diab DL.
J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. Epub 2010 Feb 19. Review.
Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Shakespeare WC, Metcalf CA 3rd, Wang Y, Sundaramoorthi R, Keenan T, Weigele M, Bohacek RS, Dalgarno DC, Sawyer TK.
Curr Opin Drug Discov Devel. 2003 Sep;6(5):729-41. Review.
Treatment of bone diseases with bisphosphonates, excluding osteoporosis.
Devogelaer JP.
Curr Opin Rheumatol. 2000 Jul;12(4):331-5. Review.
Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption.
Rubino MT, Agamennone M, Campestre C, Campiglia P, Cremasco V, Faccio R, Laghezza A, Loiodice F, Maggi D, Panza E, Rossello A, Tortorella P.
ChemMedChem. 2011 Jul 4;6(7):1258-68. doi: 10.1002/cmdc.201000540. Epub 2011 Mar 15.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on